Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31131503 | 0.90 | KDM5A (0.46) | IKBKETBK1KDM5AALOX15GAA | |
| SCHEMBL1404089 | 0.85 | — | — | |
| SCHEMBL10195707 | 0.84 | OGA (0.48) | IKBKETBK1ALOX15GAASMN1; SMN2 | |
| SCHEMBL2799494 | 0.82 | KDM5A (0.40) | IKBKETBK1KDM5ADYRK1AGSK3B | |
| SCHEMBL13574170 | 0.81 | KDM5A (0.39) | IKBKETBK1KDM5AKHK | |
| SCHEMBL1427831 | 0.81 | KDM5A (0.46) | TBK1KDM5ADYRK1AGSK3BCLK2 | |
| SCHEMBL1581899 | 0.81 | KDM5A (0.40) | KDM5ASMN1; SMN2DYRK1AGSK3BKHK | |
| SCHEMBL31276806 | 0.81 | DYRK1A (0.47) | IKBKETBK1BMPR1AACVRL1ACVR1 | |
| SCHEMBL2696054 | 0.81 | ACHE (0.44) | KDM5ABMPR1AACVRL1ACVR1CLK2 | |
| SCHEMBL574364 | 0.81 | ACHE (0.47) | KDM5ABMPR1AACVRL1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688778-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Biogen MA Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024211696-A1 | 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230406864-A1 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME LLC (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230399309-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230399309-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Guangzhou Yufan Nantu Biotechnologies Co., Ltd (CN) | 2023-12-14 | — | — | US | disclosed |
| EP-4240361-A1 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | Merck Sharp & Dohme LLC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-4223752-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Zhuhai Yufan Biotechnologies Co., Ltd (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-3781563-B1 | HPK1 INHIBITORS, PREPARATION METHOD AND APPLICATION THEREOF | ZHUHAI YUFAN BIOTECHNOLOGIES CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022098807-A1 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | MERCK SHARP & DOHME CORP. (US) | 2022-05-12 | — | — | WO | disclosed |
| EP-3450433-B1 | PURINE DERIVATIVES AS TLR7 INHIBITORS FOR TREATING E.G. SYSTEMIC LUPUS ERYTHEMATOSUS | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2021-08-18 | — | — | EP | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009150240-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2009-12-17 | — | — | WO | disclosed |
| CN-101023064-A | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMA (US) | 2007-08-22 | — | — | CN | disclosed |
| CN-101018780-A | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMA (US) | 2007-08-15 | — | — | CN | disclosed |
| EP-1786785-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1784396-A2 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021881-A2 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399309-A1 | DEUTERATED HPK1 KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, VRK1 | IKBKE 312/4885TBK1 980/4885KDM5A 1751/4885 |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | IKBKE 671/4885TBK1 1573/4885KDM5A 2700/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | IKBKE 1147/4885TBK1 716/4885KDM5A 954/4885 |
| US-20230406864-A1 | 7-AZOLE SUBSTITUTED 2-AMINOQUINAZOLINE INHIBITORS OF HPK1 | PHKG1, HIPK1, PDXK | IKBKE 285/4885TBK1 1440/4885KDM5A 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.